semaglutide

Polycystic ovary syndrome (PCOS) is now polyendocrine metabolic ovarian syndrome (PMOS), reflecting its hormonal and metabolic nature. Research highlights its endocrine roots, impacting insulin and other hormones, not just ovaries. This reclassification aims for earlier diagnosis and better management, emphasizing metabolic health alongside reproductive concerns for affected women.

Morgan Stanley maintained an equal-weight rating on Dr Reddy’s Labs, citing missed Q4FY26 estimates and a slight delay in semaglutide ramp-up. Kotak Institutional Equities recommended buying Dixon Technologies, driven by strong consumer electronics performance. Citigroup reiterated its buy on Max Financial, highlighting margin improvements and sustained growth. Macquarie rated Berger Paints underperform, despite a constructive outlook.

Docs see patients reporting irritability and loss of drive. The answer may lie in dopamine, the brain’s reward system

A groundbreaking study has unveiled that GLP-1 receptor agonists, a type of weight-loss drug, can decrease cardiovascular incidents by 13% in just under three years. These results remain consistent across different diabetes backgrounds, emphasizing long-lasting perks like diminished risks of heart attacks, strokes, and improved survival rates.

Affordable generic versions of Ozempic and Wegovy have quickly secured 20% of the Rs 1,600 crore weight-loss market following patent expiry. Early movers like Torrent and Sun Pharma are challenging Eli Lilly's Mounjaro, with generics and lower pricing boosting semaglutide's market position.

New research reveals genes influence weight loss and nausea from Ozempic and Mounjaro. A study of nearly 28,000 people found specific genetic variants predict drug effectiveness and side effects. This breakthrough could lead to personalized prescriptions, helping doctors tailor treatments for millions. Doctors may soon use genetic tests to set realistic expectations and choose the best drug for each patient.

Influencers and online communities are driving a surge in unapproved weight-loss peptides imported from China. This trend is fueled by the high cost of doctor-prescribed medications and the desire to overcome weight-loss plateaus, as the body can adapt to even potent GLP-1 drugs, leading to weight regain.

New weight-loss injections are proving effective for Indian patients, with over 40% shedding at least 10% of their body weight in a recent Delhi hospital study. While results vary, especially for those with diabetes, the therapies offer significant health benefits. Experts emphasize these are not quick fixes but valuable tools when combined with lifestyle changes for sustained weight reduction.

An Instagram reel sparks a deep dive into weight-loss peptides, leading many in India to import unapproved, trial-stage medications from China. Driven by cost and the desire to overcome weight-loss plateaus, individuals are navigating AI-simplified science and online communities to obtain these substances, bypassing official medical channels.

Online forums are leading Indians to experimental weight-loss drugs not yet approved for use. What follows is a murky chain of Chinese suppliers, local sellers, imports and self-injection that has doctors worried

Once prescribed for diabetes and obesity, GLP-1 drugs are now entering cardiology with evidence of cardiovascular benefits. The shift raises a key question — who truly stands to gain from them?

Indian pharmaceutical giants like Sun Pharma, Torrent, and Dr. Reddy's have launched affordable semaglutide, a groundbreaking weight-loss drug, following Novo Nordisk's patent expiry. This move significantly reduces therapy costs, offering patients greater access to treatment for obesity and type-2 diabetes. Torrent Pharma even introduced both oral and injectable versions, marking a significant step in addressing India's growing metabolic disorder crisis.

As semaglutide’s patent expires on March 20 the entry of generics is set to nearly halve treatment costs, opening up injectable anti-obesity treatment. But pharma firms, trying to stand out in a crowded room, are looking beyond simple price cuts, eyeing an entire weight-loss ecosystem. This could include diet plans, counselling and clinic partnerships

Weight Loss: A study has found a link between obesity and weekly usage of semaglutide. semaglutide is widely used for the treatment of diabetes. It acts like human glucagon-like peptide-1 in that it increases insulin secretion. "In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight," the study, which has been published in The New England Journal of Medicine, says.